Article List

WPRIM Management System> DCMS> Kidney Research and Clinical Practice> 2018> 37> 3

Volume: 37 Issue: 3

1. The authors' reply: Use of erythropoiesis-stimulating agents in obese hemodialysis patients.	Page:310—311
2. Use of erythropoiesis-stimulating agents in obese hemodialysis patients.	Page:308—309
3. Nephroptosis: The wandering kidney.	Page:306—307
4. Calcification of the urinary bladder and ureter in schistosomiasis.	Page:304—305
5. Membranoproliferative glomerulonephritis in a patient with chronic brucellosis.	Page:298—303
6. Use of dapagliflozin in patients with advanced diabetic kidney disease.	Page:292—297
7. Dihydroxyadenine crystal-induced nephropathy presenting with rapidly progressive renal failure.	Page:287—291
8. Predictive parameters of arteriovenous fistula maturation in patients with end-stage renal disease.	Page:277—286
9. Association of serum mineral parameters with mortality in hemodialysis patients: Data from the Korean end-stage renal disease registry.	Page:266—276
10. Efficacy of low-dose spironolactone on top of angiotensin receptor blockade in patients with glomerulonephritis.	Page:257—265
11. Anti-phospholipase A2 receptor antibody as a prognostic marker in patients with primary membranous nephropathy.	Page:248—256
12. Timing for initiation of sequential continuous renal replacement therapy in patients on extracorporeal membrane oxygenation.	Page:239—247
13. Tenofovir-induced renal tubular dysfunction among human immunodeficiency virus patients on antiretroviral therapy in Nigeria: Prospects for early detection of presymptomatic nephrotoxicity.	Page:230—238
14. The expression of two isoforms of matrix metalloproteinase-2 in aged mouse models of diabetes mellitus and chronic kidney disease.	Page:222—229
15. Puromycin aminonucleoside triggers apoptosis in podocytes by inducing endoplasmic reticulum stress.	Page:210—221
16. Noncoding RNAs as therapeutic targets in early stage diabetic kidney disease.	Page:197—209
17. Immune mechanisms in the different phases of acute tubular necrosis.	Page:185—196
18. Mineralocorticoid receptor blockade for renoprotection.	Page:183—184
19. Anti-phospholipase A2 receptor antibodies in membranous nephropathy.	Page:181—182